APHERESIS

APHERESIS was reported 50 times

APHERESIS is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 CD38-directed Cytolytic Antibody [EPC] 7 0.0012
1 Lymphocyte Growth Factor [EPC] 1 0.0008
2 Interleukin-17 Receptor A Antagonist [EPC] 1 0.0005
3 PCSK9 Inhibitor [EPC] 7 0.0003
4 Complement Inhibitor [EPC] 7 0.0001
5 Topoisomerase Inhibitor [EPC] 7 0.0001
6 Hemoglobin S Polymerization Inhibitor [EPC] 2 0.0001
7 Proteasome Inhibitor [EPC] 7 0.0001
8 Alkylating Drug [EPC] 11 0.0000
9 Penem Antibacterial [EPC] 1 0.0000
10 Leukocyte Growth Factor [EPC] 4 0.0000
11 Platinum-based Drug [EPC] 7 0.0000
12 Dihydrofolate Reductase Inhibitor Antibacterial [EPC] 2 0.0000
13 Thalidomide Analog [EPC] 10 0.0000
14 BCL-2 Inhibitor [EPC] 1 0.0000
15 Glycopeptide Antibacterial [EPC] 1 0.0000
16 Potassium Channel Blocker [EPC] 1 0.0000
17 Dietary Cholesterol Absorption Inhibitor [EPC] 1 0.0000
18 Programmed Death Receptor-1 Blocking Antibody [EPC] 1 0.0000
19 5-alpha Reductase Inhibitor [EPC] 1 0.0000
20 Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor [EPC] 1 0.0000
21 Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC] 1 0.0000
22 Corticosteroid [EPC] 10 0.0000
23 Prostacycline Vasodilator [EPC] 1 0.0000
24 Azole Antifungal [EPC] 1 0.0000
25 Kinase Inhibitor [EPC] 2 0.0000
26 CD20-directed Cytolytic Antibody [EPC] 1 0.0000
27 Angiotensin 2 Receptor Blocker [EPC] 1 0.0000
28 HMG-CoA Reductase Inhibitor [EPC] 1 0.0000
29 Folate Analog Metabolic Inhibitor [EPC] 1 0.0000
30 Tumor Necrosis Factor Blocker [EPC] 2 0.0000